Clinical trials: Chronic Obstructive Pulmonary Diseases
Chronic Obstructive Pulmonary Disease
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD
This study is a randomized, double-blind, placebo-controlled complete block cross-over study designed to assess the efficacy, safety, and pharmacokinetics of 3 dose levels of glycopyrrolate inhalation solution delivered twice…
- Trial name
- NCT06545500
- Testing
- Glycopyrrolate (85 μg), Glycopyrrolate (42.5 μg), Glycopyrrolate (14 μg)
- Where
- 7 sites in United States
- Volunteers
- 46 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Chronic Obstructive Pulmonary Disease (COPD)
Effectiveness of the WearME System for COPD Severity and Respiratory Function
This observational study evaluates the effectiveness of the WearME system in monitoring COPD severity and respiratory function by comparing its measurements to standard spirometry, capnography, and other clinical assessments in…
- Trial name
- WearME-COPD (NCT06751537)
- Where
- 2 sites in United States
- Volunteers
- 128 people
- Sponsor
- LASARRUS Clinic and Research Center
Pulmonary Disease, Chronic Obstructive
Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients
This study is designed to determine the efficacy and safety of a new long-acting beta-agonist for asthma patients (GSK159797) following dosing for 14 days.
- Trial name
- NCT00358488
- Testing
- GSK159797 (10, 15, and 20mcg), salbutamol, salmeterol 50mcg
- Where
- 6 sites in Germany, Netherlands and 3 more
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control
This study evaluated the safety and efficacy of 26 weeks treatment with indacaterol, placebo or salmeterol in patients with chronic obstructive pulmonary disease.
- Trial name
- NCT00567996
- Testing
- Indacaterol 150 μg, Salmeterol 50 μg
- Where
- 128 sites in Canada, Colombia and 13 more
- Volunteers
- 1,002 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
A Study To Investigate Safety, Blood Levels And Effects Of Giving GW642444, By Mouth, By Inhalation & By Injection
This study will involve the use of a new medicine called GW642444 being developed for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00711126
- Testing
- GW642444
- Where
- United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)
Trial will include 40 subjects and consists of 3 visits: Screening, Treatment and Follow up. A euglycemic clamp procedure and Technosphere®/Insulin (T/I) administration will occur at Visit 2 for both COPD and non COPD subjects.
- Trial name
- NCT01021891
- Testing
- Technosphere®/Insulin
- Where
- 5 sites in United States, Austria and 2 more
- Volunteers
- 39 people
- Sponsor
- Mannkind Corporation
Asthma
Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics
This study is designed to evaluate the repeat-dose safety and effectiveness of a bronchodilator inhaler relative to placebo (inactive drug inhaler) in children aged 4-11 years with asthma.
- Trial name
- NCT00308685
- Testing
- Albuterol
- Where
- 14 sites in United States
- Volunteers
- 95 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Obstructive Pulmonary Disease
Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant
The study will assess the Pharmacokinetic (PK) and safety of BGF MDI [Budesonide/glycopyrronium/formoterol (BGF) metered dose inhaler (MDI)] formulated with 2 different propellants :Hydrofluoroolefin (HFO) and Hydrofluoroalkane…
- Trial name
- NCT05477108
- Testing
- Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal)
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Safety and Tolerability QAT370 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease
This study will assess the safety and tolerability of QAT370 compared to tiotropium in patients with COPD.
- Trial name
- NCT00532350
- Testing
- QAT370, Tiotropium
- Where
- 3 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate the safety and efficacy of inhaled PT001 compared to placebo and tiotropium in patients with mild to moderate chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00871182
- Testing
- Inhaled PT001, Tiotropium Handihaler
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- Pearl Therapeutics, Inc.
Psoriasis
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in Asian subjects with moderate to…
- Trial name
- NCT01815424
- Testing
- CP-690,550
- Where
- 24 sites in China, South Korea and 1 more
- Volunteers
- 266 people
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive (COPD), Hypercapnia
Effectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia (EVALECO)
The purpose of this study is to evaluate the effectiveness and clinical efficiency of combining home non-invasive ventilation (NIV) with a continuous remote telemonitoring (TM) system in patients with Chronic Obstructive…
- Trial name
- EVALECO (NCT07679646)
- Testing
- Home Non-Invasive Ventilation and Telemonitoring
- Where
- Spain
- Volunteers
- 92 people
- Sponsor
- Air Liquide Healthcare Spain
COPD, Chronic Obstructive Pulmonary Disease
Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)
This is a trial of 12 weeks of treatment with nebulized SUN-101 using an Investigational eFlow® Closed System (CS) nebulizer in subjects with chronic obstructive pulmonary disease (COPD) according to the Global Initiative for…
- Trial name
- GOLDEN-4 (NCT02347774)
- Testing
- SUN-101 50 mcg BID eFlow (CS) nebulizer, SUN-101 25 mcg BID eFlow (CS) nebulizer
- Where
- 45 sites in United States
- Volunteers
- 641 people
- Sponsor
- Sunovion Respiratory Development Inc.
COPD
In This Study, the Sponsor Would Like to Collaborate with Institution and Investigator to Aggregate Participants Data and to Pilot Its Software Algorithm Using Machine Learning and Threshold Based Methods for Predicting Exacerbations and Deterioration Within a 60 Days Period Post-discharge
In this study, the sponsor would like to collaborate with Institution and Investigator to aggregate participants data and to pilot its software algorithm using machine learning and threshold based methods for predicting…
- Trial name
- NCT06798688
- Testing
- A non-invasive cardio-respiratory sensor will be applied on the subjects to measure parameters to identify exacerbations
- Volunteers
- 20 people
- Sponsor
- Respiree Pte Ltd
Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation
Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease
The purpose of this trial is to investigate if roflumilast can reduce the neutrophilic inflammation at acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- TREAT (NCT01473758)
- Testing
- Roflumilast
- Where
- 2 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry
This study aims to assess the ethnic sensitivity of GSK3862995B in terms of safety, tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) in healthy participants of Chinese, Japanese, and European ancestry to enable the…
- Trial name
- NCT06979518
- Testing
- GSK3862995B
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH
The aim of the present study is to evaluate the effect of aclidinium bromide 400 μg BID compared with placebo on COPD symptoms in a symptomatic patients population with moderate COPD and chronic bronchitis, and particularly…
- Trial name
- M-34273-46 (NCT02375724)
- Testing
- Aclidinium Bromide
- Where
- 24 sites in Germany, Hungary and 3 more
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
COPD
Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Bioequivalence Study of Tiotropium Bromide Inhalation Powder 18 μg
- Trial name
- ARBORUS (NCT05986591)
- Testing
- Test Product - Tiotropium Bromide Inhalation Powder 18 mcg, Spiriva Handihaler (Tiotropium Bromide) 18 mcg
- Where
- 33 sites in United States, India
- Volunteers
- 335 people
- Sponsor
- Xiromed LLC
Pulmonary Disease, Chronic Obstructive
Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.
Post marketing Surveillance to gain insights into the effects of therapy with Spiriva® (tiotropium bromide) on health-related quality of life in COPD patients who stopped smoking during treatment and to obtain safety data…
- Trial name
- NCT02172547
- Testing
- Spiriva
- Volunteers
- 10,821 people
- Sponsor
- Boehringer Ingelheim
Asthma-COPD Overlap Syndrome
A Non-interventional Study to Investigate the Current Situation of Asthma-COPD Overlap Syndrome in Patients Over Age 40 With Persistent Airflow Limitation in China
To investigate the distributions of the patients with ACOS, asthma and COPD over age 40 with chronic airflow limitation in China.
- Trial name
- NCT02600221
- Where
- 13 sites in China
- Volunteers
- 2,016 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.